Skip to main content

Table 2 Non-responders demographics, classification, and reduction in migraine days per month

From: Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders

 

Demographics

% of migraine days per month

Response

 

Age

Years w/migraine

Gender

BMI

MIDAS

Classification

Baseline

1 month

2 months

3 months

% reduction (3 months vs baseline)

Patient 1

45

21

Female

38.7

little

EM (HF)

44.2

16.1

25.0

50.0

31.3

Patient 2

43

25

Female

40.9

moderate

EM (HF)

38.7

45.5

15.6

50.0

4.3

Patient 3

22

1

Female

22.2

little

EM (LF)

12.9

8.0

8.3

3.4

48.9

Patient 4

40

31

Female

23.5

severe

EM (HF)

32.5

37.5

22.6

20.7

17.2

Patient 5

22

8

Female

26.6

severe

EM (LF)

13.8

19.4

6.7

4.5

26.1

Patient 6

37

31

Female

26.6

severe

EM (HF)

46.9

26.7

23.8

32.1

41.3

Patient 7

61

39

Male

17.7

mild

EM (HF)

36.4

13.6

33.3

43.5

17.1

Patient 8

24

15

Male

31.8

little

EM (HF)

26.8

6.7

13.6

25.0

43.7

Patient 9

33

4

Female

24.3

severe

CM

54.3

29.2

50.0

27.1

34.7

Patient 10

30

15

Female

22.1

severe

CM

80.0

59.3

54.2

50.0

31.9

Patient 11

63

21

Male

23.3

mild

CM

51.3

32.0

24.1

23.8

48.0

Patient 12

52

37

Female

20.9

severe

CM

57.8

64.7

40.7

36.0

18.4

Patient 13

26

1

Female

22.8

severe

CM

63.0

40.0

27.6

43.8

41.1

Patient 14

38

25

Female

20

severe

CM

50.0

37.9

39.3

31.8

27.3

Patient 15

22

2

Female

25

severe

CM

56.7

22.0

39.4

33.3

44.3

Patient 16

21

8

Female

20.4

moderate

CM

66.7

45.8

37.5

42.1

37.3

Patient 17

27

16

Female

23.6

moderate

CM

80.6

84.8

64.5

60.0

13.5

Patient 18

35

20

Female

23.2

severe

CM

51.5

31.8

37.9

35.3

32.0

Patient 19

53

45

Female

21.8

severe

CM

100

96.3

85.7

95.7

7.4